Immutep Limited (IMMP) Stock Price & Analysis
Immutep Limited (IMMP) — MoonshotScore 20/100 (Weak band), calculated Nov 18, 2026. Price $3.25 (+1.25%), as of the Nov 18, 2026 trading session; market cap $24.0M.
Educational signal · not a buy or sell recommendation · How to read this
Immutep Limited · IMMP · NASDAQ
Immutep Limited is an Australian biotechnology company specializing in the research and development of immunotherapeutic product candidates for cancer and autoimmune diseases. Its lead candidate, eftilagimod alpha, is currently in Phase IIb clinical trials for metastatic breast cancer, supported by a broad pipeline and strategic collaborations.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Immutep (IMMP)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality and a strained balance sheet, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Strained; Valuation: Fair; Growth Durability: Growing; Momentum: Falling.
- quarterly revenue A$11M (Q4 FY2026, quarter ended Jun 2026)
- Altman Z -10.04 · Piotroski F 3
- ROE -77.3% · ROA -42.5% · current ratio 5.69
Holding back: weak fundamentals, balance-sheet strain, weak price trend
Helping: an attractive price
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 19 | Weak | |
| 20 | Weak | |
| 20 | Weak | |
| 20 | Weak | |
| 20 | Weak | |
| 20 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $3.25 | |
| Change on the day | +1.25% | |
| 52-week range | $2.66 – $70.60 | |
| Market capitalisation | $24.0M | — |
| Shares traded on the day | 76.3K |
Price & events
Other perspectives
Council score for Immutep (IMMP): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
3 lenses, 3 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Immutep (IMMP), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Immutep Limited (IMMP) is listed on NASDAQ. It employs 53 people and is led by Marc Voigt. In Q4 FY2026 it reported revenue of A$11M and net income of -A$35M. The market values it at $24.0M.
What do the latest results show for Immutep (IMMP)?
Short answer · as of
The most recent reported quarter, Q4 FY2026, carried revenue of A$11M.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2026 | A$11M | -A$35M | -A$4.74 (diluted) |
| Q2 FY2026 | A$6M | -A$45M | -A$6.10 (diluted) |
| Q4 FY2025 | A$2M | -A$39M | -A$5.36 (diluted) |
| Q2 FY2025 | A$3M | -A$22M | -A$3.08 (diluted) |
What are the financial strengths and risks for Immutep (IMMP)?
Short answer
The MoonshotScore pillars rate an attractive price as strengths. What is holding it back is weak fundamentals, balance-sheet strain, weak price trend. The distress and quality screens read Altman Z -10.04 · Piotroski F 3. Trailing ratios: ROE -77.3% · ROA -42.5% · current ratio 5.69.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -10.04 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-77.3%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
How does Immutep compare with its peers?
Short answer
Immutep's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.28 Nov 18, 2026 | $552M | 91 5-pillar Nov 18, 2026 | |
| $3.02 Nov 18, 2026 | $255M | 90 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $15.26 Nov 18, 2026 | $85.5M | 82 5-pillar Nov 18, 2026 | |
| $11.25 Nov 18, 2026 | $102M | 82 5-pillar Nov 18, 2026 | |
| $3.89 Nov 18, 2026 | $169M | 72 5-pillar Nov 18, 2026 | |
| $1.96 Nov 18, 2026 | $186M | 69 5-pillar Nov 18, 2026 | |
| $12.48 Nov 18, 2026 | $884M | 69 5-pillar Nov 18, 2026 | |
| $9.30 Nov 18, 2026 | $546M | 68 5-pillar Nov 18, 2026 | |
| $29.68 Nov 18, 2026 | $993M | 64 5-pillar Nov 18, 2026 | |
| $8.32 Nov 18, 2026 | $813M | 63 5-pillar Nov 18, 2026 | |
| Immutep (IMMP) — this page | $3.25 | $24.0M | 20 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held IMMP in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported IMMP in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Immutep (IMMP)?
- Immutep Reports Encouraging Disease-Free Survival from EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma
- Immutep Announces First Survival Data from EFTISARC-NEO Trial
- Immutep Reports Encouraging Survival Data From Phase 2 Cancer Trial
- Reported Earlier, Immutep Granted New US Patent 12,788,796 Covering Efti Combined With PD-1 Pathway Inhibitors, Bringing Total US Patents In Family To Five
What Investors Ask About Immutep (IMMP)
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
What does the MoonshotScore mean for IMMP?
IMMP carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is IMMP a good stock to buy?
Stock Expert AI does not rate IMMP buy, sell or hold. Immutep Limited carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the IMMP stock price today?
The last price recorded for Immutep Limited (IMMP), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the key factors to evaluate for IMMP?
Immutep Limited (IMMP) holds a MoonshotScore in the low range. This asset represents a critical value driver due to its advanced clinical stage and potential to address an area of high unmet medical need. Not financial advice.
How frequently does IMMP data refresh on this page?
IMMP's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven IMMP's recent stock price performance?
Immutep Limited (IMMP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Advanced clinical pipeline with lead candidate eftilagimod alpha in Phase IIb for metastatic breast cancer. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IMMP overvalued or undervalued right now?
Immutep Limited (IMMP) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of IMMP?
Fractional-share availability for Immutep Limited (IMMP) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
How can I track IMMP's earnings and financial reports?
Immutep Limited (IMMP) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for IMMP earnings announcements.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 14 figures on this page — 7 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com